References
- PAK VIEKIRA (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]North Chicago, ILAbbVie, Inc. approved December 2014. Available from. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206619s017lbl.pdfAccessed August 28, 2018
- VIEKIRAX (ombitasvir, paritaprevir, and ritonavir tablets) [summary of product characteristics]North Chicago, ILAbbVie, Inc. approved January 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdfAccessed August 28, 2018
- EXVIERA (dasabuvir tablets) [summary of product characteristics]North Chicago, ILAbbVie, Inc. approved January 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdfAccessed August 28, 2018
- FerenciPTreatment options for anti-HCV treatment-experienced patientsClin Liv Dis2012124950
- American Association for the Study of Liver Diseases and the Infectious Diseases Society of AmericaHCV guidance: recommendations for testing, managing, and treating hepatitis C2018 Available from: https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_May_24_2018b.pdfAccessed August 28, 2018